NCT00796003 - A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

JNJ-30979754 15 mg/m2

JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.

DRUG

JNJ-30979754 20 mg/m2

Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.

Trial Locations (7)

Unknown

Fukuoka

Hamamatsu

Hidaka

Nagasaki

Nagoya

Shinjuku

Tokyo